Hepion rises after completing enrollment in NASH drug trial
05/12/2022 16:04
** Shares of liver disease drug developer Hepion
Pharmaceuticals Inc HEPA.O climb 7.8% to 41 cents
** Set for best day in nearly three weeks, if gains hold
** HEPA says it has completed enrollment of participants for
its mid-stage trial of rencofilstat, an investigational drug
being developed to treat NASH; co enrolls 60 patients in 12
weeks urn:newsml:reuters.com:*:nGNX8jYLC2
** Non-alcoholic steatohepatitis, or NASH, is a serious
progressive liver disease that is one of the fastest-growing
causes of liver transplant with no FDA-approved treatments
** Stock has fallen 66.6% this year up to Friday's close
(Reporting by Ruhi Soni in Bengaluru)
((Ruhi.Soni@thomsonreuters.com
Twitter: https://twitter.com/ruhithere))
Recent news on Hepion Pharmaceuticals
See all newsBrief: Hepion Pharmaceuticals Executes Binding Letter Of Intent With New Day Diagnostics To Commercialize Diagnostic Tests For Celiac Disease, Respiratory Multiplex, H. Pylori And Hcc
Brief: Hepion Pharma In-Licenses Diagnostic Tests from New Day Diagnostics- SEC Filing
Brief: Hepion Pharmaceuticals Announces Termination Of Merger Agreement With Pharma Two B
Brief: Hepion Pharmaceuticals Issues Letter to Shareholders Urging Support for Proposed Merger with Pharma Two B
Brief: Pharma Two B Plans To Go Public Via Merger With Hepion Pharmaceuticals, Concurrent $11.5 Mln Private Placement